TRIM25 Regulates Oxaliplatin Resistance in Colorectal Cancer by Promoting EZH2 Stability

Sha Zhou(Sun Yat-sen University), Zhenlin Hou(Sun Yat-sen University)
Research Square
August 20, 2020
10.21203/rs.3.rs-60545/v1
Cited by 2

Related Papers

Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer
|Autophagy|2023|387
TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability
|Cell Death and Disease|2021|65
TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability
|Research Square|2020|2